Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alkermes Plc (ALKS)  
$24.68 0.24 (0.98%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 183,678,000
Market Cap: 4.53(B)
Last Volume: 775,760 Avg Vol: 773,595
52 Week Range: $23.37 - $33.63
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Delivery

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  581
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 35,000
Total Buy Value $0 $0 $0 $815,735
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 15,666 15,666 89,488 206,962
Total Sell Value $454,291 $454,291 $2,700,159 $6,056,962
Total People Sold 3 3 4 6
Total Sell Transactions 3 3 7 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 1496
  Page 3 of 60  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2024-02-18 4 D $32.18 $60,144 D/D (1,869) 66,292     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2024-02-18 4 OE $0.00 $0 D/D 6,355 68,161     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-18 4 D $32.18 $60,144 D/D (1,869) 106,199     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-18 4 OE $0.00 $0 D/D 6,355 108,068     -
   Parisi Samuel Joseph VP, Finance (Interim PAO)   •       •      –    2024-02-18 4 D $32.18 $22,719 D/D (706) 5,228     -
   Parisi Samuel Joseph VP, Finance (Interim PAO)   •       •      –    2024-02-18 4 OE $0.00 $0 D/D 2,034 5,934     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-18 4 D $32.18 $127,143 D/D (3,951) 92,883     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-18 4 OE $0.00 $0 D/D 8,897 96,834     -
   Laurencin Cato T Director   •       •      –    2024-02-15 4 AS $31.85 $85,677 D/D (2,690) 15,169 -24%     
   Laurencin Cato T Director   •       •      –    2024-02-15 4 OE $22.52 $60,579 D/D 2,690 17,859     -
   Mckeon Brian P Director   •       •      –    2024-02-10 4 D $27.32 $29,724 D/D (1,088) 23,141     -
   Mckeon Brian P Director   •       •      –    2024-02-10 4 OE $0.00 $0 D/D 4,533 24,229     -
   Daglio David Angelo Jr. Director   •       •      –    2024-02-10 4 D $27.32 $29,724 D/D (1,088) 23,141     -
   Daglio David Angelo Jr. Director   •       •      –    2024-02-10 4 OE $0.00 $0 D/D 4,533 24,229     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2024-02-08 4 D $26.77 $294,657 D/D (11,007) 139,945     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2024-02-08 4 A $0.00 $0 D/D 36,835 150,952     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-08 4 D $26.77 $85,209 D/D (3,183) 268,744     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-08 4 A $0.00 $0 D/D 21,485 271,927     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-08 4 D $26.77 $409,046 D/D (15,280) 87,937     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-08 4 A $0.00 $0 D/D 46,658 103,217     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-08 4 D $26.77 $217,827 D/D (8,137) 101,713     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-08 4 A $0.00 $0 D/D 27,012 109,850     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-08 4 D $26.77 $227,090 D/D (8,483) 147,707     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-08 4 A $0.00 $0 D/D 28,240 156,190     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2024-02-08 4 D $26.77 $2,456,335 D/D (91,757) 1,179,675     -
  1496 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 60
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us